Vir Biotechnology announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VIR-5500, an investigational prostate-specific membrane antigen (PSMA)-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC).
The designation, which is intended to facilitate and expedite the development and review of drugs addressing serious conditions with unmet needs, follows Phase 1 data reported earlier this year by Vir Biotechnology that VIR-5500 was generally well tolerated and exhibited promising antitumor activity in patients with mCRPC. Specific response rates, efficacy data, and safety details were not disclosed in the announcement.
VIR-5500 is co-developed by Vir Biotechnology and Astellas Pharma Inc. under a global strategic collaboration. The companies anticipate initiating Phase 3 trials of VIR-5500 in 2027.
Key finding
The FDA granted Fast Track designation to VIR-5500 for late-line mCRPC based on its potential to address an unmet clinical need, though detailed efficacy data from the ongoing Phase 1 study have not been publicly disseminated.
Study Design
| Trial | Open-label, non-randomized Phase 1 clinical trial (NCT05997615) |
|---|---|
| Population | Patients with mCRPC or metastatic hormone-sensitive prostate cancer (mHSPC) |
| Treatment | VIR-5500 monotherapy (taxane-naïve mCRPC, radioligand therapy–naïve mCRPC, radioligand therapy–exposed mCRPC); VIR-5500 + enzalutamide (early-line mCRPC); VIR-5500 + docetaxel (early-line mCRPC); VIR-5500 + darolutamide (mHSPC) |
| Primary endpoint | Safety and pharmacokinetics |
| Key secondary endpoints | Preliminary efficacy |
The Phase 1 study evaluates VIR-5500 across six dose-expansion cohorts in both monotherapy and combinatorial regimen settings, reflecting the potential clinical utility of VIR-5500 across multiple stages of the prostate cancer disease continuum. The trial is designed to assess safety, pharmacokinetics, and preliminary efficacy ahead of the planned Phase 3 development.
Results and Safety
Phase 1 data reported earlier in 2026 indicated that VIR-5500 was generally well tolerated and showed promising antitumor activity in patients with mCRPC, according to Vir Biotechnology. However, the company did not disclose specific outcomes in this announcement, such as objective responses, prostate-specific antigen response rates, or progression-free survival estimates.
Similarly, no detailed safety data, including rates of adverse events or cytokine release syndrome, were included in the Fast Track designation announcement. Full Phase 1 results have not yet been reported to the public.
Clinical Context
T-cell engagers have established meaningful roles in the treatment of hematologic malignancies, but their application in solid tumors has historically been confounded by systemic toxicity arising from on-target, off-tumor T-cell activation. VIR-5500’s PRO-XTEN® dual-masking technology is designed to address this limitation by keeping the molecule inactive in circulation and releasing it only within the tumor microenvironment, where tumor-specific proteases cleave the mask. This approach aims to widen the therapeutic index of the TCE and potentially allow for less frequent dosing, though whether these mechanistic advantages translate into a clinically differentiated safety and efficacy profile compared to unmasked TCEs or existing PSMA-directed therapies has not been demonstrated.
Late-line mCRPC represents a population with limited treatment options and poor prognosis following progression on androgen receptor pathway inhibitors and taxane-based chemotherapy. The Fast Track designation signals FDA recognition of the unmet need in this clinical context, but confirmatory evidence of VIR-5500’s benefit will depend on results of the anticipated Phase 3 program, which is anticipated to start in 2027.
Sources
- Vir Biotechnology. “Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer.” Press release. 2026. View source.
